ArticleBMC veterinary research2025
Regulatory role of lncRNA MSTRG.11540.1 on the novel-m1192-3p/CYP2C70 axis in modulating albendazole resistance in Haemonchus contortus.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTo investigate the role of long non-coding RNAs (lncRNAs) in the regulation of albendazole resistance in Haemonchus contortus (H. contortus) through competing endogenous RNA (ceRNA) mechanisms, a ceRNA network analysis was performed based on RNA-seq data from albendazole-sensitive and albendazole-resistant strains. Starting with significantly upregulated lncRNAs and incorporating functional enrichment analysis of predicted target genes, a potential regulatory axis-MSTRG.11540.1/novel-m1192-3p/HCON_00073890 (CYP2C70)-was identified from the ceRNA network. Transcriptomic analysis revealed that MSTRG.11540.1 and CYP2C70 were significantly upregulated (fold changes of 1.20 and 4.01, respectively; P < 0.01), while novel-m1192-3p was significantly downregulated (fold change: 5.91; P < 0.05) in resistant strains. This study employed dual-luciferase reporter assays and RNA interference (RNAi) to validate the interactions and functional relevance of the candidate RNA molecules. Furthermore, an egg hatch assay (EHA) was conducted to assess the impact of the lncRNA-mediated ceRNA axis on albendazole resistance. The aim was to provide insights into the molecular mechanisms by which lncRNAs may regulate drug resistance in H. contortus.
resultsA dual-luciferase reporter plasmid containing the predicted binding sites was constructed to investigate the candidate ceRNA axis MSTRG.11540.1/novel-m1192-3p/CYP2C70. The interaction assay revealed that novel-m1192-3p binds to MSTRG.11540.1, but no direct binding was observed between novel-m1192-3p and its predicted target gene CYP2C70. However, overexpression of novel-m1192-3p downregulated the expression of both MSTRG.11540.1 (45.71% reduction compared to NC group, P > 0.05) and CYP2C70 (40.74% reduction versus NC group, P < 0.05). Subsequent RNAi experiments confirmed the existence of the MSTRG.11540.1/novel-m1192-3p/CYP2C70 regulatory axis. Moreover, EHA results showed that knockdown of MSTRG.11540.1 significantly decreased the LD
conclusionsThis study confirmed that the lncRNA-mediated ceRNA axis MSTRG.11540.1/novel-m1192-3p/CYP2C70 is involved in the regulation of albendazole resistance in H. contortus. These findings provide potential molecular targets for further elucidation of anthelmintic resistance mechanisms and the development of novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.